Haiying Que

Abstract Fibrosis is a severe pathological outcome of many chronic diseases, yet the therapeutic potential of targeting the altered major histocompatibility complex (MHC) class I immunopeptidome remains largely unexplored. Here we characterized the MHC class I immunopeptidomes from both fibrotic foci of human idiopathic pulmonary fibrosis lung explants and bleomycin-treated mice, identifying a diverse repertoire of fibrosis-associated peptides.

Clinical trials of agents targeting the Wnt/β-catenin signaling pathway was summarized in Table 4, and Fig. 5 shown the timeline of clinical trials of drugs targeting Wnt/β-catenin signaling pathway. Timeline of clinical trials of drugs targeting Wnt/β-catenin signaling pathway. This figure illustrates Part 5: Clinical applications of drugs targeting the Wnt/β-catenin signaling pathway, emphasizing the advancement of clinical trials for these pharmacological agents.